Kenvue's $1.9B Cash Flow vs. $8.6B Debt: Who's Right?
Two institutional investors — Readystate Asset Management and Nykredit A/S — have disclosed purchases of a combined 454,719 Kenvue shares in recent filings, apparently betting the company's $1.9 billi
Kenvue's $1.9B Cash Flow vs. $8.6B Debt: Who's Right?
NEW YORK, September 7 —
Kenvue Inc. (KVUE), the maker of Tylenol, Neutrogena, and Listerine, just snapped a three-quarter EPS beat streak with a 2.8% Q2 miss, even as two institutional investors bet 454,719 shares on the proposition that $1.9 billion in annual free cash flow can service $8.61 billion in debt. One of those assumptions just got shakier.
- Q2 EPS of $0.31 missed the consensus by 2.8%, ending three straight quarters of double-digit beats.
- $8.61B in gross debt against $1.11B in cash; TTM free cash flow of $1.91B.
- Readystate Asset Management and Nykredit A/S disclosed a combined 454,719-share purchase in recent filings.
What Three Consecutive Beats Actually Priced In
Kenvue, incorporated in 2022 and headquartered in Summit, New Jersey, sells OTC medicines under Tylenol, Zyrtec, and Benadryl, skin-care products under Neutrogena, Aveeno, and Rogaine, and household staples including Listerine, BAND-AID, and Johnson's Baby across North America, Europe, Asia-Pacific, and Latin America. The prior three quarters produced EPS beats of 7.6%, 22.5%, and 23.1%, a run that led the Street to model conservatively and expect reliable delivery. Q2 ended that run. Trailing revenue of $15.41 billion grew 3.0% year-over-year, decent but not enough to hold the premium once the beat streak ended.
The Leverage Math That Now Applies
Readystate Asset Management's 200,000-share purchase and Nykredit A/S's 254,719-share position rest on a familiar institutional thesis: at 58.4% gross margin and billion in TTM free cash flow, Kenvue generates enough cash to service its debt while holding a 15.1x forward P/E. The sensitivity to even a modest FCF shortfall is what a DCF model makes plain. With only $1.11 billion in cash against $8.61 billion in gross debt, there is no balance-sheet buffer to absorb multi-quarter earnings softening. The Q2 miss, per the August 6 8-K, is a single data point; the institutional thesis is built on the assumption it stays one.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| KVUE | $36.0B | 15.1x | +1.7% |
| KDP | $44.3B | 12.9x | +18.0% |
| AMCR | $20.9B | 10.4x | +9.9% |
| GEHC | $31.1B | 12.7x | -11.9% |
| HLN | $42.2B | 15.4x | -1.4% |
| TFC | $63.1B | 10.4x | +12.3% |
Q3 Free Cash Flow Will Settle the Argument
CFO Heather Howlett's open-market sale of 3,700 shares at $18.11 on June 10, 2026, sits below Kenvue's current $18.74, making it poorly timed in hindsight rather than prescient. More pointed: APAC Group President Anindya Dasgupta exercised options for 16,418 shares on July 31, one week before the August 6 earnings 8-K. Option exercises carry less signal than open-market sales, but proximity to an earnings release invites scrutiny. The real verdict arrives next quarter: free cash flow holding near the TTM pace vindicates the institutional thesis and relegates Q2 to seasonal noise; a second shortfall shifts the debt load from background risk to the primary valuation variable. Run the free Kenvue Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Two institutional investors — Readystate Asset Management and Nykredit A/S — have disclosed purchases of a combined 454,719 Kenvue shares in recent filings, apparently betting the company's $1.9 billion in annual free cash flow can support an $8.6 billion debt load; yet Q2 2026 just delivered Kenvue's first EPS miss in four quarters, putting that free-cash-flow thesis to its first real test.